Pioglitazone: a review of Japanese clinical studies

Current Medical Research and Opinion
S Baba

Abstract

Pioglitazone, a new thiazolidinedione agent,has been shown to increase insulin sensitivity in clinical trials. Pioglitazone HCI was rapidly absorbed within one hour, achieved peak concentrations at 2-3 h, and was eliminated from serum at 24-36 h. Pioglitazone demonstrated dose-dependent pharmacokinetics. Food did not significantly affect the pharmacokinetic profile of pioglitazone. The pharmacokinetic profile of sulfonylurea agents was not significantly altered by concurrent administration with pioglitazone. Pharmacokinetic studies in healthy volunteers and in patients with type 2 diabetes indicated that pioglitazone may be administered once daily. In patients with type 2 diabetes, pioglitazone as monotherapy and in combination with sulfonylureas or an alpha-glucosidase inhibitor significantly reduced fasting blood glucose, HbA1c, triglycerides, and free fatty acids, and significantly increased HDL-cholesterol. Pioglitazone demonstrated either minor increases or decreases in cholesterol with no adverse effect on LDL-cholesterol. No patients experienced jaundice or ALT elevations > or = three times the upper limit of normal. Adverse events were mild and transient; all subjects returned to their baseline health status or laborato...Continue Reading

Citations

Oct 12, 2010·Pharmaceuticals·Johanna K Distefano, Richard M Watanabe
Apr 11, 2012·Drug and Chemical Toxicology·Sajal Kumar SahaSitesh Chandra Bachar
Nov 22, 2002·Current Medical Research and Opinion·Kathy Ann LaCivita, Gustavo Villarreal
Dec 23, 2003·Current Medical Research and Opinion·Hiroaki SeinoRyuzo Abe
May 21, 2014·Journal of Diabetes Investigation·Takashi Kadowaki, Kazuoki Kondo
Apr 17, 2012·Pharmacology, Biochemistry, and Behavior·Rachna Gupta, Lalit Kumar Gupta
Apr 12, 2003·British Journal of Clinical Pharmacology·Klemens BuddeDavid Eckland
Oct 6, 2020·Naunyn-Schmiedeberg's Archives of Pharmacology·Aparna NatarajanThangarajan Rajkumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

© 2022 Meta ULC. All rights reserved